

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

20-596 / S-019

Trade Name: Epivir

Generic Name: (Lamivudine)

Sponsor: GlaxoSmithKline

Approval Date: December 24, 2002

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-596 / S-019

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
EA/FONSI	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative and Correspondence Document(s)	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-596 / S-019

APPROVAL LETTER



NDA 20-596/S-019

GlaxoSmithKline
Attn: Kevin A. Miller
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709

Dear Mr. Miller:

Please refer to your supplemental new drug application dated July 1, 2002, received July 2, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for EPIVIR[®] (lamivudine) Oral Solution, 10 mg/mL.

This "Changes Being Effected in 30 days" supplemental new drug application provides for a) an alternate manufacturing, packaging, and testing site at _____ b) changes to the _____ and c) an _____ in the typical batch size + _____

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Vasavi Reddy, R.Ph., Regulatory Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Stephen P. Miller, Ph.D.
Chemistry Team Leader for the
Division of Antiviral Drug Products, (HFD-530)
DNDC III, Office of New Drug Chemistry
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/


Stephen Paul Miller
12/24/02 02:14:16 PM
NDA 20596 S-019 is approved

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-596 / S-019

CHEMISTRY REVIEW(S)

SUPPLEMENTAL NDA CHEMIST'S REVIEW		DUE DATE 1/2/03	1. ORGANIZATION HFD-530	2. NDA NUMBER 20-596	
3. NAME AND ADDRESS OF APPLICANT GlaxoSmithKline Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709 Attn: Kevin A. Miller			4. TYPE OF SUPPLEMENT CBE-30		
			5. DOCUMENT(S)		
			NUMBERS SCM-019	DATED 7/1/02	RECEIVED 7/2/02
6. NAME OF DRUG EPIVIR® Oral Solution			7. NONPROPRIETARY NAME lamivudine oral solution		
8. SUPPLEMENT PROVIDES FOR:			9. AMENDMENTS/DATES		
10. PHARMACOLOGICAL CATEGORY Anti-HIV		11. HOW DISPENSED <input checked="" type="checkbox"/> R <input type="checkbox"/> OTC		12. RELATED IND/NDA/DMF(s)	
13. DOSAGE FORM(S) Oral solution			14. POTENCY (CIES) 10 mg/mL		
15. CHEMICAL NAME AND STRUCTURE (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one			16. MEMORANDA		
					
17. COMMENTS					
<p>Epivir (lamivudine) oral solution is currently manufactured at _____ With this Supplement the sponsor wishes to establish an alternate manufacturing, packaging, and testing site at GlaxoSmithKline, _____ Changes to the equipment (which is of the same design and operating principle) and a change in the _____ including the _____ are also described. Based upon reviews of the relevant DMFs the changes in the container-closure system are not expected to have any impact on product quality. The composition of the oral solution is not changed although the typical batch size is increased to _____. The specifications of the oral solution are not changed. Batch analyses are provided for 3 batches manufactured at _____ and 3 batches manufactured at _____. The batches are comparable. Six months of satisfactory stability data obtained at _____ and _____ are provided for 3 batches manufactured in Mississauga. The currently-approved shelf life of 24 months will continue to apply. The first commercial batch manufactured at Mississauga will be placed on stability as will one annual batch. An Establishment Evaluation Request was submitted and an Overall Recommendation of "Acceptable" has been made.</p>					
18. CONCLUSIONS AND RECOMMENDATIONS					
This Supplement is therefore recommended for approval.					
19. REVIEWER					
NAME George Lunn, Ph.D.		SIGNATURE [signed electronically in DFS]		DATE OF DRAFT REVIEW 12/17/02	
20. CONCURRENCE: HFD-530/SMiller [signed electronically in DFS]					
DFS CC LIST	<input type="checkbox"/> L	GLunn	<input type="checkbox"/> L	Med: BStyrt	PharmTox
L = Action Letter	<input checked="" type="checkbox"/> RL	SMiller	<input checked="" type="checkbox"/> RL	PM: CLincoln	Micro
R = Review	<input checked="" type="checkbox"/> RL	CChen		Biopharm	

WITHHOLD 5 PAGE(S)

B4 Chemistry Review

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

George Lunn
12/23/02 11:30:32 AM
CHEMIST

Epivir solution transfer to Mississauga

Stephen Paul Miller
12/24/02 09:42:43 AM
CHEMIST